EZH2 and cancer: Over-expression of EZH2 has been strongly linked with cancer progression partly because PRC2 inhibits E-cadherin expression, which promotes epithelial-to-mesenchymal transition (EMT) in cancer cells [28], a phenomenon that is reminiscent of CSCs or CSLCs.